Novel multiresistance cfr plasmids in linezolid-resistant methicillin-resistant Staphylococcus epidermidis and vancomycin-resistant Enterococcus faecium (VRE) from a hospital outbreak: co-location of cfr and optrA in VRE
Author(s) -
Alexandros Lazaris,
David C. Coleman,
Angela Kearns,
Bruno Pichon,
Peter M. Kinnevey,
Megan R. Earls,
Breida Boyle,
Brian O’Connell,
Gráinne I. Brennan,
Anna C. Shore
Publication year - 2017
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkx292
Subject(s) - linezolid , enterococcus faecium , staphylococcus epidermidis , microbiology and biotechnology , outbreak , medicine , vancomycin resistant enterococcus , enterococcus , vancomycin , methicillin resistant staphylococcus aureus , biology , staphylococcus aureus , virology , antibiotics , bacteria , genetics
Linezolid is often the drug of last resort to treat infections caused by Gram-positive cocci. Linezolid resistance can be mutational (23S rRNA or L-protein) or, less commonly, acquired [predominantly cfr, conferring resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins and streptogramin A compounds (PhLOPSA) or optrA, encoding oxazolidinone and phenicol resistance].
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom